PDCD1 and CTLA-4 antibodies, which are immune checkpoint inhibitors, have been approved for the treatment of cancers including non-small cell lung cancer (NSCLC) and melanoma, and have improved the prognosis of patients with these cancers [39, 40]. Here, CTLA4 is linked to cancer.